Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Cara Therapeutics Stock Quote

Cara Therapeutics (NASDAQ: CARA)

Price as of May 24, 2024, 4:00 p.m. ET

Cara Therapeutics Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
CARA -79.54% -96.28% -48.19% -95%
S&P +27.79% +87.71% +13.41% +198%

Cara Therapeutics Company Info

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

News & Analysis

The Fool has written over 200 articles on Cara Therapeutics.


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.